Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06781359
Recruiting Observational

Study on Plasmablastic Lymphoma Patients

NCT06781359 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Italiana Linfomi - ETS
Phase
Observational
Started
2025-02-14
Last updated
2026-08-19

Condition(s) studied

Plasmablastic Lymphoma

Study summary

This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.

Eligibility

Sex
ALL
Min age
15 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022 * Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report * Age \> 18 years old * Availability of complete medical records * Availability of histopathological material requested by the study Exclusion Criteria: * Any other histology than PBL * Lack of complete medical records * Lack of histopathological material requested by the study

Primary outcome measure(s)

  • Overall Survival (OS) — 36 months
    OS is defined as the time from the diagnosis to death for any cause or last clinical contact for censored patients.

Trial sites (23)

FacilityCityRegionStatus
IRCCS Centro di Riferimento Oncologico di Aviano, Divisione di Oncologia e dei Tumori immuno-correlati Aviano PN Recruiting
Ospedale C.e G. Mazzoni, U.O.C. di Ematologia Ascoli Piceno Italy Recruiting
ASST Spedali Civili di Brescia, Ematologia Brescia Italy Active Not Recruiting
A.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo Cuneo Italy Recruiting
Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia Florence Italy Recruiting
ASST -Fatebenefratelli - Polo Luigi Sacco Oncologia Milan Italy Recruiting
ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia Milan Italy Recruiting
Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia Milan Italy Active Not Recruiting
Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Ematologia Milan Italy Active Not Recruiting
Fondazione IRCCS San Gerardo dei Tintori, Ematologia Monza Italy Recruiting
AOU Maggiore della Caritа di Novara, SCDU Ematologia Novara Italy Active Not Recruiting
Azienda Ospedaliera Universitaria di Padova, Ematologia Padova Italy Not Yet Recruiting
Presidio ospedaliero A. Tortora, U.O. Onco-ematologia Pagani Italy Not Yet Recruiting
Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia Reggio Emilia Italy Recruiting
Azienda Ospedaliera Universitaria Sant' Andrea, Ematologia Roma Italy Recruiting
Policlinico Umberto I - Università La Sapienza, Istituto Ematologia, Dipartimento di Medicina Traslazionale e di Precisione Roma Italy Recruiting
Universitа Cattolica S. Cuore, Ematologia Roma Italy Not Yet Recruiting
Azienda Ospedaliero Universitaria Senese, U.O.C. Ematologia Siena Italy Recruiting
A.O.U. Città della Salute e della Scienza di Torino, Ematologia Universitaria Torino Italy Not Yet Recruiting
A.O.U. Città della Salute e della Scienza di Torino, S.C. Ematologia Torino Italy Recruiting
Ospedale S. Chiara, S.S. di Ematologia Trento Italy Recruiting
ULSS2 Marca Trevigiana, Ospedale Ca' Foncello, S.C di Ematologia Treviso Italy Active Not Recruiting
ULSS 8 Berica - Ospedale S. Bortolo, Ematologia Vicenza Italy Recruiting

More Fondazione Italiana Linfomi - ETS trials in Italy

Primary Cardiac Lymphoma: Italian Multicenter Experience Recruiting
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy Recruiting
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. Active, not recruiting
Long-term Assessment of Chlormethine Gel in Mycosis Fungoides Starting soon
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients Active, not recruiting

Other trials for the same condition

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06781359 on ClinicalTrials.gov ↗ ← All trials in Italy